ADVM - NASDAQ
Adverum Biotechnologies, Inc.
$4.36
+0.0000%Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotAdverum Biotechnologies, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Adverum Biotechnologies, Inc. Cash Flow Statement
ADVM • NASDAQ
| Adverum Biotechnologies, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-130.9M | -122.1M | -154.5M | -145.5M | -117.5M | -64.5M | -72.6M | -56.1M | -113.7M | -47.5M | -25.4M | -5.3M | -1.8M | |
3.7M | 5.6M | 6.5M | 4.6M | 4.2M | 1.6M | 1.8M | 2.1M | 1.6M | 812K | 162K | 26K | 1K | |
0.0 | 0.0 | 0.0 | 3.8M | 863K | -1.3M | -1.3M | 593K | 60.7M | 801K | 963K | 1.7M | -19K | |
14.4M | 17.6M | 20.1M | 25.2M | 20.4M | 9.9M | 13.4M | 8.7M | 11.4M | 11.5M | 8.6M | 515K | 76K | |
19.6M | 16.5M | -51K | -25K | 75K | 58K | 6.4M | 70K | 8K | 218K | 18K | 885K | 16K | |
911K | -8.5M | 19.9M | 4.1M | 12.7M | 5.1M | -1.6M | -756K | 1.6M | -1.2M | 10M | -70K | 470K | |
-92.5M | -90.9M | -108.1M | -107.8M | -79.3M | -49.2M | -54M | -45.4M | -38.4M | -35.3M | -5.6M | -2.2M | -1.3M | |
INVESTING ACTIVITIES | |||||||||||||
-388K | -808K | -11.8M | -15.1M | -11.8M | -19.2M | -809K | -1M | -2.4M | -3M | -943K | -91K | -3K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.4M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-101.9M | -36.7M | -104.4M | -407.5M | -570.4M | -197.3M | -78.7M | -209.8M | -38.8M | -88.4M | (0.0) | (0.0) | (0.0) | |
60.4M | 134.4M | 257.9M | 501.3M | 302.1M | 148.5M | 149M | 88.6M | 37.7M | 49.9M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 38.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
-41.9M | (96.9M) | (141.7M) | (78.7M) | -280.2M | -68.1M | (69.4M) | -122.2M | (38.8M) | -41.6M | -943K | -91K | -3K | |
FINANCING ACTIVITIES | |||||||||||||
119.4M | 489K | 607K | 1.7M | 344.3M | 25.9M | 70.2M | 16.5M | 0.0 | 139M | 116.5M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -240K | -61K | -112K | -175K | 0.0 | 0.0 | 0.0 | 2M | 1.5M | 500K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4M | (0.0) | (0.0) | |
642K | -420K | 0.0 | 952K | 11.7M | 2.4M | -63K | 229K | 556K | -94K | -1.9M | -20K | 0.0 | |
120M | 69K | 607K | 2.4M | 356M | 28.2M | 69.9M | 16.7M | 556K | 138.9M | 165.4M | 2.5M | 500K | |
CASH FLOW SUMMARY | |||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -774K | -143K | -9K | -11K | -7K | 9K | |
-14.3M | 6M | 34.2M | -26.7M | -3.5M | -89.1M | 85.4M | -151.7M | 822K | 61.9M | 158.8M | 207K | -761K | |
77M | 70.9M | 36.7M | 63.4M | 66.9M | 155.9M | 70.5M | 222.2M | 221.3M | 159.4M | 564K | 357K | 1.1M | |
62.6M | 77M | 70.9M | 36.7M | 63.4M | 66.9M | 155.9M | 70.5M | 222.2M | 221.3M | 159.4M | 564K | 357K | |
-92.9M | -91.7M | -119.9M | -123M | -91.1M | -68.4M | -54.8M | -46.4M | -40.8M | -38.3M | -6.6M | -2.3M | -1.3M |
SEC Filings
ADVM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | December 09, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 19, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 24, 2025 | October 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 22, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 12, 2025 | August 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 18, 2025 | June 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 14, 2025 | March 31, 2025 | 2025 |
Related Guides
Continue your ADVM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.